Ludwig In the News

January 2, 2020
Pharma Times

Vaccitech Oncology Limited (VOLT), a strategic collaboration of the Ludwig Institute for Cancer Research and the biotech Vaccitech, has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600 immunotherapy as a treatment option for patients with non-small cell lung cancer (NSCLC).

Notice
?

You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?

Continue
Cancel